Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

  1. Jänne, P.A.
  2. Van Den Heuvel, M.M.
  3. Barlesi, F.
  4. Cobo, M.
  5. Mazieres, J.
  6. Crinò, L.
  7. Orlov, S.
  8. Blackhall, F.
  9. Wolf, J.
  10. Garrido, P.
  11. Poltoratskiy, A.
  12. Mariani, G.
  13. Ghiorghiu, D.
  14. Kilgour, E.
  15. Smith, P.
  16. Kohlmann, A.
  17. Carlile, D.J.
  18. Lawrence, D.
  19. Bowen, K.
  20. Vansteenkiste, J.
Revue:
JAMA - Journal of the American Medical Association

ISSN: 1538-3598 0098-7484

Année de publication: 2017

Volumen: 317

Número: 18

Pages: 1844-1853

Type: Article

DOI: 10.1001/JAMA.2017.3438 GOOGLE SCHOLAR

Objectifs de Développement Durable